

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[← Back](#)

[Patient & Caregiver Resources & Treatment](#)

[Refer a Patient](#)

Radiochemistry & Molecular Imaging Probes

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)


[Give to MSK](#)



Jason S. Lewis
Scientific Director

At Memorial Sloan Kettering, researchers have translated numerous new radiopharmaceuticals into the clinic for both imaging and therapy purposes. The Radiochemistry and Molecular Imaging Probe (RMIP) Core Facility serves these investigators by supplying a variety of radiopharmaceuticals, including radiolabeled small molecules, peptides, antibodies, and nanoparticles that can be imaged by methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). It also supplies nonradioactive molecular imaging probes for use with non-nuclear detection systems. Our services support both basic research investigations and patient imaging.

[View More](#) →





Radiopharmacist Serge Lyashchenko preparing a reagent in the cyclotron facility.

<

>

Featured News

IN THE CLINIC



[How Our New Particle Accelerator Will Make Cancer Imaging and Treatment More Precise](#)

Friday, June 27, 2014

The launch of a 20-ton instrument and a facility for producing radioactive imaging molecules will allow our doctors and scientists to monitor cancers in unparalleled detail.



[Novel Cancer-Targeting Investigational Nanoparticle Receives FDA IND Approval for First-In-Human Trial](#)

Monday, January 31, 2011

Researchers at Memorial Sloan Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.


People




Jason S. Lewis

Scientific Director

Members




Serge K.
Lyashchenko
Director



Shake Ahmmed
RMIP Core
Radiopharmacist



Sam
Frackowiak
Manager, RMIP Core
Manufacturing



Hijin A.
Park
Lead, Nuclear Pharmacist



Andrew
Rivera
Radiopharmacy Tech I



Giovanni Saint-Victor
RMIP Core Systems
Specialist



Tricia Taylor
RMIP Core Project
Manager



Tuan
Tran
Manager, RMIP Core
Manufacturing



Angelo
Valdivia
Sr. Radiopharmacy
Technician



Jiong "Lilly"
Wu
Research Technician, Sr.



Christopher Yung
RMIP Core
Radiopharmacist

Alumni
+

Get in Touch

✉ lewisj2@mskcc.org

▼ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) 

[Giving](#) 

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▼ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) 

[Graduate medical education](#)

[MSK Library](#) 

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center